
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Psychiatrists and other physicians are sometimes pressured to participate in torture and less extreme methods to extract information "for the greater good." Does the good ever outweigh the bad?
See the article,




